免疫蛋白酶体抑制可预防肾移植慢性抗体介导排斥反应
慢性抗体介导排斥是肾移植后移植物功能丧失的主因,目前缺乏药物。研究在大鼠肾移植模型中用LMP7选择性抑制剂ONX 0914,发现其抑制免疫蛋白酶体诱导、减少B/浆细胞及供体特异性抗体,减轻移植物损伤并保留功能。
要点
- 免疫蛋白酶体抑制剂ONX 0914可抑制大鼠肾移植慢性抗体介导排斥。
- ONX 0914减少B细胞、浆细胞及供体特异性同种抗体产生。
- ONX 0914减轻移植物浸润与沉积,改善慢性肾病并保留肾功能。
核心结论
- 免疫蛋白酶体在慢性肾移植排斥中起关键作用,选择性抑制是潜在治疗策略。
研究设计与样本
- 临床前动物实验:Fischer至Lewis大鼠同种异体肾移植模型,使用LMP7(β5i)选择性抑制剂ONX 0914。
主要发现
- ONX 0914抑制免疫器官和肾移植物的免疫蛋白酶体诱导。
- ONX 0914减少B细胞和浆细胞数量,抑制供体特异性同种抗体产生。
- ONX 0914减少移植物中T细胞、B细胞、巨噬细胞浸润及干扰素-γ、白介素-17、IgG和补体沉积。
- ONX 0914改善慢性肾病并保留肾移植功能,使受体长期存活。
临床怎么用
- 提示选择性免疫蛋白酶体抑制可能用于防治肾移植慢性抗体介导排斥,尚需临床验证。
局限性
- 证据来自大鼠模型,尚未在人体中验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic antibody-mediated rejection is the major cause of fading allograft function and loss after renal transplantation. Currently, pharmacological agents for the suppression of chronic antibody-mediated rejection are lacking. Non-selective proteasome inhibitors suppress antibody-mediated allograft rejection. However, extensive adverse side effects of these inhibitors severely limit their application. In contrast, immunoproteasome inhibition is effective in preclinical models of autoimmune diseases and was applied over weeks without obvious adverse side effects. ONX 0914, an immunoproteasome subunit LMP7 (β5i)-selective inhibitor, impeded the chronic rejection of kidneys transplanted from Fischer to allogeneic Lewis rats. ONX 0914 inhibited immunoproteasome induction both in immune organs and renal allografts. Selective immunoproteasome inhibition reduced the numbers of B and plasma cells, and suppressed donor-specific alloantibody production. The infiltration of T cells, B cells and macrophages as well as interferon-γ, interleukin-17, IgG and complement deposition were reduced in renal allografts of ONX 0914-treated recipients. Chronic nephropathy was ameliorated and renal allograft function preserved, enabling long-term survival of recipients. Thus, our studies define a critical role of the immunoproteasome in chronic kidney allograft rejection and suggest immunoproteasome inhibition as a promising therapeutic approach to suppress chronic antibody-mediated rejection.
引用
- Li J, Basler M, Alvarez G, et al. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation. Kidney Int. 2017. PMID: 29229189. doi:10.1016/j.kint.2017.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。